Balcinrenone
Small moleculeexperimental
Clinical trial activity
18 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02484729)
Timeline
Indications
Studied for
- Body Fluids · Phase 2
- Cardiovascular Diseases · Phase 1
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 2
- Electrolytes · Phase 2
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 3
- Heart Failure, Diastolic · Phase 1
- Kidney Failure, Chronic · Phase 2
- Liver Diseases · Phase 1
- Pharmacokinetics · Phase 1
- Pharmacology · Phase 1
- Renal Insufficiency, Chronic · Phase 2
- Safety · Phase 1
Mechanism of action
- Mineralocorticoid receptorMODULATOR
NR3C2 modulator
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2- Mol. weight
- 399.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3916929 ↗
Also known as
- azd9977
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06979388 | Phase 1 | May 20, 2025 | AstraZeneca, Parexel |
| NCT06651021 | Phase 1 | Dec 3, 2024 | AstraZeneca |
| NCT06388616 | Phase 1 | May 2, 2024 | AstraZeneca |
| NCT06350123 | Phase 2 | May 1, 2024 | AstraZeneca |
| NCT06307652 | Phase 3 | Apr 12, 2024 | AstraZeneca |
| NCT05884866 | Phase 2 | May 8, 2023 | Klinikum Nuernberg - Klinikum Nord |
| NCT04798222 | Phase 1 | Jun 29, 2021 | AstraZeneca, CTC Bio, Inc., Parexel |
| NCT04686591 | Phase 1 | Dec 21, 2020 | AstraZeneca, Quotient |
| NCT04595370 | Phase 2 | Dec 8, 2020 | AstraZeneca, University of Glasgow |
| NCT04469907 | Phase 1 | Jun 22, 2020 | AstraZeneca |
| NCT03843060 | Phase 1 | Feb 22, 2019 | AstraZeneca |
| NCT03801967 | Phase 1 | Jan 24, 2019 | AstraZeneca, Parexel, University of Ankara |
| NCT03682497 | Phase 1 | Oct 1, 2018 | AstraZeneca |
| NCT03450759 | Phase 1 | Mar 28, 2018 | AstraZeneca, Parexel |
| NCT03435276 | Phase 1 | Feb 27, 2018 | AstraZeneca, Parexel |
| NCT02560363 | Phase 1 | Nov 1, 2015 | AstraZeneca, Parexel |
| NCT02532998 | Phase 1 | Sep 1, 2015 | AstraZeneca, Parexel |
| NCT02484729 | Phase 1 | Jul 1, 2015 | AstraZeneca, Parexel |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 17 | 17 | 3 | 2015 |
| Parexel | For profit | 8 | 0 | 1 | 2015 |
| CTC Bio, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Klinikum Nuernberg - Klinikum Nord | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Quotient | For profit | 1 | 0 | 1 | 2020 |
| University of Ankara | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Glasgow | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1